From Dealroom · · 50s
VeraMorph gets NIH grant for breast cancer drug
Pharmaceutical startup VeraMorph secures $2.1M NIH grant to develop oral breast cancer treatment.
In brief
Pharmaceutical startup VeraMorph secures $2.1M NIH grant to develop oral breast cancer treatment. VeraMorph, a specialty pharmaceutical startup, received a $2.1 million NIH grant to fund preclinical work on an oral fulvestrant formulation for metastatic breast cancer. Originally reported by Dealroom.
Grant secured
VeraMorph, a specialty pharmaceutical startup, received a $2.1 million SBIR Phase II grant from the National Institutes of Health to fund IND-enabling work on its oral formulation of fulvestrant.
New CEO appointed
Daniel O'Connor, former chief strategy officer of Eagle Pharmaceuticals, was named chief executive officer to lead the company's clinical strategy.
Drug development timeline
The company targets clinical entry in 2027 and an NDA filing in 2029 after completing preclinical studies with the grant funds.
The headline
VeraMorph, a specialty pharmaceutical startup, received a $2.1 million NIH grant to fund preclinical work on an oral fulvestrant formulation for metastatic breast cancer.
